Cymabay offering
WebJan 23, 2024 · CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need, announced that it has commenced an underwritten public offering of its common stock and pre-funded warrants. WebJan 24, 2024 · CymaBay is selling 10,000,000 shares of common stock and pre-funded warrants to purchase 2,142,857 shares of common stock in the offering. The shares of common stock are being sold at a public ...
Cymabay offering
Did you know?
WebNov 18, 2024 · --CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with ... WebJan 23, 2024 · CymaBay Therapeutics (NASDAQ:CBAY) +7.6% aftermarket on Monday announced that it has commenced an underwritten public offering of its common stock and pre-funded warrants.
WebJan 24, 2024 · CymaBay is selling 10,000,000 shares of common stock and pre-funded warrants to purchase 2,142,857 shares of common stock in the offering. The shares of common stock are being sold at a public... WebJan 24, 2024 · CymaBay is selling 10,000,000 shares of common stock and pre-funded warrants to purchase 2,142,857 shares of common stock in the offering. The shares of common stock are being sold at a public offering price of $7.00 per share, and the pre-funded warrants are being sold at a public offering price of $6.9999 per underlying share.
WebNov 17, 2024 · CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need, announced that it has commenced an underwritten public offering of its common stock and pre-funded warrants. WebSep 5, 2024 · Earnings Estimate Revisions for CymaBay Therapeutics Inc. For the fiscal year ending December 2024, this company is expected to earn -$1.21 per share, which is a change of 4.7% from the year-ago ...
WebJan 30, 2024 · CymaBay sold 11,821,428 shares of its common stock in the offering, including 1,821,428 shares pursuant to the full exercise of the underwriters’ option to purchase additional shares, at a...
WebJan 24, 2024 · The gross offering proceeds to CymaBay from this offering are expected to be approximately $85.0 million, before deducting the underwriting discount and other estimated offering expenses, and excluding the exercise of any pre-funded warrants. All shares of common stock and pre-funded warrants to be sold in the offering are being … cam u go live on twitch highWebRisks and uncertainties relating to CymaBay Therapeutics and its business can be found in the "Risk Factors" section of CymaBay Therapeutics' Amendment No. 1 to Form S-1, filed with the SEC on July 17, 2014 (No. 333-195127) related to the offering. CymaBay Therapeutics undertakes no duty or obligation to update any forward-looking statements ... camunda download windowsWebNov 17, 2024 · NEWARK, Calif., Nov. 17, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative... fish and chips valley angleseyWebJan 24, 2024 · CymaBay is selling 10,000,000 shares of common stock and pre-funded warrants to purchase 2,142,857 shares of common stock in the offering. The shares of common stock are being sold at a public... camunda open source githubWebJan 30, 2024 · NEWARK, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics (Nasdaq:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it has commenced an underwritten public offering of its common … fish and chips vanWebThe offering is expected to close on February 1, 2024, subject to the satisfaction of customary closing conditions. ... The securities described above are being offered by CymaBay pursuant to a shelf registration statement previously filed with and declared effective by the Securities and Exchange Commission (the "SEC"). camulodunum roman townWebNEWARK, CA -- (Marketwired) -- 07/15/15 -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY) announced today the pricing of its underwritten public offering of 7,120,000 shares of its common stock at a price to the public of $2.81 per share, for expected gross proceeds of approximately $20 million. fish and chips vancouver island